RxDoctor Payments Data

Adam Marcovitch, MD

Ophthalmology · State College, PANPI 1235132051

Payments from drug & device makers

$435in general payments, 2019–2025

Across 14 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$182
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$91
  • AbbVie$63
  • Bausch & Lomb Americas Inc.$42
  • Aerie Pharmaceuticals, Inc.$21
  • Shire North American Group Inc$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$435 in reported general payments places this provider in the 30th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$360,471
Medicare patients
895
Services billed
2,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast101$140,996
LumiganBimatoprost216$114,231
RestasisCyclosporine52$47,029
Travoprost126$41,226
RhopressaNetarsudil Mesylate70$35,760
Prednisolone Acetate625$31,586
Cyclosporine53$28,418
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol100$27,374
Brimonidine Tartrate203$23,286
ProlensaBromfenac Sodium69$22,923
Bromfenac Sodium113$21,581
Latanoprost1,275$19,798
VyzultaLatanoprostene Bunod36$18,361
CombiganBrimonidine Tartrate/Timolol36$14,472
Alphagan PBrimonidine Tartrate31$11,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$63$187,580335 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$42$159,357137 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$21$44,81487 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$91$28,53583 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →